Toggle navigation

UNLOCKING THE POTENTIAL OF
EARLY TREATMENT

Consider starting treatment as early as possible after diagnosis

Cameron
age 2.5

Infantile-onset (Type 1) SMA
treated with SPINRAZA

Type 1 SMA Cameron fishing with dad

In some cases, genetic testing is used to diagnose SMA in infants before symptoms develop. At day 183 of an open-label study, some presymptomatic infants treated with SPINRAZA achieved age-appropriate milestones.

Achievement of HINE Section 2 motor milestones

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information for additional Important Safety Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.

This information is not intended to replace discussions with your healthcare provider.


INDICATION

SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.